All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAR-T Immunotherapy has achieved unprecedented response rates in B-cell malignancies and myeloma patients. While the application of CAR-T therapy in solid tumors is not satisfactory. The lack of cancer-specific antigens, poor trafficking and penetration of CAR-T cells into malignant sites, and tumor microenvironment have led to this challenge. Currently, a wide range of target antigens are being studied for solid tumor therapy, and the ErbB family serves as a rich source of antigen candidates based on a variety of characteristics including prevalence, immunogenicity, and specificity.
Fig.1 TME hurdles in CAR-T Cell Immune Therapy for Solid Tumors.1
To address these issues, Creative Biolabs provides a robust and effective pan-ErbB-targeted combination CAR-T cell engineering service to speed up global customers' solid research. The pan-ErbB-targeted combination CAR-T strategy incorporates the promiscuous ErbB ligand T1E, placed upstream of a second-generation CAR design with a chimeric cytokine receptor (CCR). This approach could simultaneously direct T-cells specifically target all ErbB1 homo- and heterodimers, the ErbB 2/3 heterodimer, and all ErbB4 homo- and heterodimers expressing tumor cells with potent cytotoxic activity against a broad range of tumor types, decreasing the risk of immune evasion. Powered by our years of experience in the CAR-T field, we provide a one-stop pan-ErbB-targeted combination CAR-T cell engineering service, including from CAR design & construction, to function validation to speed up customers' solid research.
Fig.2 Schematic of pan-ErbB-targeted combination CAR-T cell engineering. (Creative Biolabs)
Customized CAR Design & Construction
Competent research team |
|
One-stop services
Reliable and reputable experiment systems |
Q1: What are the safety & challenges considerations for ErbB-targeted CARs?
A1: Several criteria need to be taken into account:
If you are interested in our CellRapeutics™ pan-ErbB-targeted combination CAR-T cell engineering service, please don't hesitate to contact us. Our experienced scientists try our best to meet the most challenging requirements and deliver the best answer for global customer satisfaction.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION